JP7821188B2 - カンプトテシン化合物、その調製方法、及びその適用 - Google Patents

カンプトテシン化合物、その調製方法、及びその適用

Info

Publication number
JP7821188B2
JP7821188B2 JP2023544762A JP2023544762A JP7821188B2 JP 7821188 B2 JP7821188 B2 JP 7821188B2 JP 2023544762 A JP2023544762 A JP 2023544762A JP 2023544762 A JP2023544762 A JP 2023544762A JP 7821188 B2 JP7821188 B2 JP 7821188B2
Authority
JP
Japan
Prior art keywords
compound
formula
group
reaction
carried out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023544762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506819A (ja
Inventor
チアン ティエン，
イータオ ジャン，
ユー ミャオ，
ボー ワン，
ジアン イェ，
シャオベイ ワン，
デリャン リー，
フェン リー，
ホンメイ ソン，
Original Assignee
シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド filed Critical シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド
Publication of JP2024506819A publication Critical patent/JP2024506819A/ja
Priority to JP2025123923A priority Critical patent/JP2025160318A/ja
Priority to JP2025123921A priority patent/JP2025160317A/ja
Application granted granted Critical
Publication of JP7821188B2 publication Critical patent/JP7821188B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2023544762A 2021-02-05 2022-01-27 カンプトテシン化合物、その調製方法、及びその適用 Active JP7821188B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025123923A JP2025160318A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用
JP2025123921A JP2025160317A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202110159956 2021-02-05
CN202110159956.6 2021-02-05
CN202110533304 2021-05-17
CN202110533304.4 2021-05-17
CN202110718245 2021-06-28
CN202110718245.8 2021-06-28
CN202110936768.X 2021-08-16
CN202110936768 2021-08-16
CN202111355330 2021-11-16
CN202111355330.9 2021-11-16
PCT/CN2022/074328 WO2022166762A1 (zh) 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025123923A Division JP2025160318A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用
JP2025123921A Division JP2025160317A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用

Publications (2)

Publication Number Publication Date
JP2024506819A JP2024506819A (ja) 2024-02-15
JP7821188B2 true JP7821188B2 (ja) 2026-02-26

Family

ID=82741966

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023544762A Active JP7821188B2 (ja) 2021-02-05 2022-01-27 カンプトテシン化合物、その調製方法、及びその適用
JP2025123921A Pending JP2025160317A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用
JP2025123923A Pending JP2025160318A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025123921A Pending JP2025160317A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用
JP2025123923A Pending JP2025160318A (ja) 2021-02-05 2025-07-24 カンプトテシン化合物、その調製方法、及びその適用

Country Status (9)

Country Link
US (3) US20240158410A1 (enExample)
EP (3) EP4613335A3 (enExample)
JP (3) JP7821188B2 (enExample)
KR (3) KR20250119655A (enExample)
CN (3) CN117567478B (enExample)
AU (1) AU2022216696A1 (enExample)
CA (1) CA3209426A1 (enExample)
MX (1) MX2023008716A (enExample)
WO (1) WO2022166762A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025160318A (ja) * 2021-02-05 2025-10-22 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法、及びその適用

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4516357T3 (da) 2020-09-30 2026-04-27 Duality Biologics Suzhou Co Ltd Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
EP4227310A4 (en) * 2020-10-12 2024-11-06 Sichuan Baili Pharmaceutical Co. Ltd. CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
JP2024532768A (ja) * 2021-08-19 2024-09-10 ハイナン シムセレ ザイミン ファーマシューティカル カンパニー リミテッド カンプトテシン誘導体、その薬物組成物およびその応用
US20250059143A1 (en) * 2021-10-26 2025-02-20 Shanghai Best-Link Bioscience, Llc Camptothecin derivative intermediate, and preparation method therefor and use thereof
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン，インコーポレイテッド 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
TW202344252A (zh) * 2022-05-09 2023-11-16 大陸商同宜醫藥（蘇州）有限公司 一種喜樹鹼衍生物，基於其的抗體－藥物偶聯物和藥物組成物，及其應用
JP2025515988A (ja) 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
EP4562051A1 (en) * 2022-07-26 2025-06-04 Immunome, Inc. Immunoconjugates and methods
CN120225528A (zh) * 2022-09-02 2025-06-27 默沙东有限责任公司 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途
CN121064211A (zh) * 2022-09-09 2025-12-05 杭州爱科瑞思生物医药有限公司 喜树碱-7-乙基胺衍生物及其制备方法和应用
AU2023349279A1 (en) * 2022-09-30 2025-05-15 Beone Medicines I Gmbh Ligand-drug conjugate of exatecan analogue, and medical use thereof
KR20250079213A (ko) 2022-10-09 2025-06-04 라노바 메디신즈 리미티드 화합물, 조성물 및 방법
KR20250079227A (ko) * 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
WO2024114318A1 (zh) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
CN116870187A (zh) * 2022-12-29 2023-10-13 杭州爱科瑞思生物医药有限公司 N-氧杂环烷基取代的喜树碱衍生物的抗体偶联药物
CN116712563A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 N-卤代烷基取代的喜树碱衍生物的抗体偶联药物
CN116712562A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 N-叠氮烷基取代的喜树碱衍生物的抗体偶联药物
WO2024158996A2 (en) * 2023-01-25 2024-08-02 Zeno Management, Inc. Immunoconjugates and methods
IL322897A (en) * 2023-02-23 2025-10-01 Phrontline Biopharma Hangzhou Co Ltd Camptothecin derivatives and conjugates, methods for their preparation and medical uses
KR20250152646A (ko) * 2023-03-01 2025-10-23 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 인데노[1,2-b]퀴놀린-10,13-디온 유도체의 제조 방법
EP4692091A1 (en) * 2023-04-07 2026-02-11 Changchun Genescience Pharmaceutical Co., Ltd. Camptothecin derivative, and pharmaceutical composition, preparation method therefor and use thereof
CN116478051B (zh) * 2023-04-13 2024-06-21 戊言医药科技（上海）有限公司 一种贝洛替康盐酸盐及其关键中间体的制备方法
WO2024227432A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用
CN120826405A (zh) * 2023-05-04 2025-10-21 四川科伦博泰生物医药股份有限公司 具有靶向作用的偶联物及其制备方法和用途
CN117417346B (zh) * 2023-09-11 2025-07-25 常州合全药业有限公司 喜树碱类衍生物的制备方法
KR20250059577A (ko) 2023-10-24 2025-05-07 삼성디스플레이 주식회사 표시 장치
CN122161833A (zh) * 2023-11-15 2026-06-05 四川科伦博泰生物医药股份有限公司 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途
CN120058720A (zh) * 2024-01-08 2025-05-30 杭州爱科瑞思生物医药有限公司 7-含羟胺结构取代的烷基喜树碱衍生物的制备及其应用
CN120058721A (zh) * 2024-01-08 2025-05-30 杭州爱科瑞思生物医药有限公司 7-氟烷基取代的喜树碱衍生物的制备及其应用
WO2025162049A1 (zh) * 2024-02-02 2025-08-07 长春金赛药业有限责任公司 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用
WO2025242090A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 喜树碱衍生物及其中间体的制备方法
WO2026046398A1 (en) * 2024-08-30 2026-03-05 Hansoh Bio Llc Novel camptothecin derivative and conjugate thereof, preparation method therefor and application thereof
WO2026158370A1 (zh) * 2025-01-24 2026-07-30 四川科伦博泰生物医药股份有限公司 具有生物活性的化合物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195665A1 (en) 2018-04-06 2019-10-10 Seattle Genetics, Inc. Camptothecin peptide conjugates
WO2019236954A1 (en) 2018-06-07 2019-12-12 Seattle Genetics, Inc. Camptothecin conjugates
WO2020219287A1 (en) 2019-04-26 2020-10-29 Immunogen, Inc. Camptothecin derivatives

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
DE69635560T2 (de) * 1995-06-21 2006-08-17 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Camptothecinanaloge, Verfahren zur ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
CN100408582C (zh) * 2004-02-12 2008-08-06 中国人民解放军第二军医大学 高喜树碱类化合物及其制备方法和用途
EP3442979A4 (en) * 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey topoisomerase poisons
CN110891942B (zh) * 2017-07-14 2022-06-07 四川科伦博泰生物医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
CN119219654A (zh) * 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
UA130338C2 (uk) * 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
JP7408646B2 (ja) * 2018-09-30 2024-01-05 ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途
KR20240104214A (ko) * 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
CN110357897A (zh) * 2019-07-26 2019-10-22 上海健康医学院 一种具有抗肿瘤活性的喜树碱衍生物及其制备方法和应用
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
US20230101735A1 (en) * 2020-01-22 2023-03-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
BR112022024930A2 (pt) * 2020-06-08 2022-12-27 Baili Bio Chengdu Pharmaceutical Co Ltd Fármaco de camptotecina possuindo unidade de conexão hidrofílica de alta estabilidade e conjugado do mesmo
WO2022078259A1 (zh) * 2020-10-12 2022-04-21 四川百利药业有限责任公司 一种氘代的喜树碱衍生物及其抗体药物偶联物
AU2022216696A1 (en) * 2021-02-05 2023-08-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
US20240252665A1 (en) * 2021-06-02 2024-08-01 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Chemical coupling linker and use thereof
MX2023012920A (es) * 2021-06-02 2023-11-13 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Conjugado anticuerpo-farmaco y metodo de preparacion y uso del mismo.
US11814394B2 (en) * 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN117567487A (zh) * 2023-11-27 2024-02-20 金宏气体股份有限公司 双核Ag(I)配合物晶体、制备方法、负载物、装置及应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195665A1 (en) 2018-04-06 2019-10-10 Seattle Genetics, Inc. Camptothecin peptide conjugates
WO2019236954A1 (en) 2018-06-07 2019-12-12 Seattle Genetics, Inc. Camptothecin conjugates
WO2020219287A1 (en) 2019-04-26 2020-10-29 Immunogen, Inc. Camptothecin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACS Medicinal Chemistry Letters，2019年，10(10)，P.1386-1392

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025160318A (ja) * 2021-02-05 2025-10-22 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法、及びその適用
JP2025160317A (ja) * 2021-02-05 2025-10-22 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法、及びその適用

Also Published As

Publication number Publication date
EP4628165A2 (en) 2025-10-08
US20260152510A1 (en) 2026-06-04
JP2025160318A (ja) 2025-10-22
CN120058723A (zh) 2025-05-30
CN117567478B (zh) 2025-03-21
US20240158410A1 (en) 2024-05-16
CN116829561B (zh) 2026-07-31
US20250346606A1 (en) 2025-11-13
MX2023008716A (es) 2023-08-02
EP4613335A2 (en) 2025-09-10
KR20250120438A (ko) 2025-08-08
CN116829561A (zh) 2023-09-29
EP4613335A3 (en) 2025-12-10
CN117567478A (zh) 2024-02-20
EP4289851A4 (en) 2025-10-15
KR20230142710A (ko) 2023-10-11
EP4289851A1 (en) 2023-12-13
KR20250119655A (ko) 2025-08-07
EP4628165A3 (en) 2026-03-11
JP2025160317A (ja) 2025-10-22
JP2024506819A (ja) 2024-02-15
CA3209426A1 (en) 2022-08-11
AU2022216696A1 (en) 2023-08-17
WO2022166762A1 (zh) 2022-08-11

Similar Documents

Publication Publication Date Title
JP2025160317A (ja) カンプトテシン化合物、その調製方法、及びその適用
JP2025515988A (ja) カンプトテシン化合物、その調製方法及びその使用
CN101495486B (zh) 具有抗肿瘤活性的喜树碱衍生物
JP2023552610A (ja) 新規カンプトテシン誘導体、それを含む組成物およびその使用
CN115124533A (zh) 四环类衍生物、其制备方法和其医药上的用途
JP2025526425A (ja) 抗体薬物複合体に適した毒素分子
WO2025036489A1 (zh) 一种氰基芳香环衍生物及其在医药上的应用
CN101495485B (zh) 具有抗肿瘤活性的喜树碱衍生物
HK40101679A (en) Camptothecin compound, preparation method therefor, and application thereof
HK40101679B (en) Camptothecin compound, preparation method therefor, and application thereof
WO2026098309A1 (zh) 多并环类化合物及其制备方法和用途
CN120858098A (zh) 稠环化合物及其制备方法和应用
US20260102507A1 (en) Camptothecin derivative for treating or preventing cancer and antibody-drug conjugate thereof
CN120053678A (zh) 一种高喜树碱类抗体偶联药物、其制备方法及应用
TW202610628A (zh) 磺醯胺化合物及其在醫藥上的應用
CN120923507A (zh) 一种喹唑啉酮大环化合物及其制备方法和应用
HK1135692B (en) Camptothecin derivatives with antitumor activity
JP2010500970A (ja) 抗腫瘍活性を有するカンプトテシン誘導体
HK1135693B (en) Camptothecin derivatives with antitumor activity
HK1135691B (en) Camptothecin derivatives with antitumor activity

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260213

R150 Certificate of patent or registration of utility model

Ref document number: 7821188

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150